Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort

STK11段 免疫疗法 克拉斯 队列 医学 癌症 肿瘤科 突变 癌症免疫疗法 内科学 生物 遗传学 基因 结直肠癌
作者
Andrea Olsen,Alexandra Lebedeva,Polina Nosova,V. Nikulin,Margarita Sharova,E. Ignatova,Vladislav Mileyko,Maxim Ivanov
出处
期刊:Tumori Journal [SAGE Publishing]
卷期号:110 (2): 146-152 被引量:2
标识
DOI:10.1177/03008916231204441
摘要

Introduction: Immune checkpoint inhibitors are highly effective in treating various cancers. We analyzed the significance of the KRAS/STK11 co-mutation in relation to the efficacy of immune checkpoint inhibitors in pan-cancer patient cohort. Methods: We analyzed data from open-access research: MSK-IMPACT (molecular profiling data from patients receiving systemic antitumor therapy) and MSK-TMB (molecular profiling data from patients receiving immune checkpoint inhibitors). In both studies, high throughput sequencing was used for molecular profiling. Results: A total of 10,336 patients receiving antitumor therapy (MSK-IMPACT study) and 1661 patients receiving immune checkpoint inhibitors (MSK-TMB study) were included in the analysis. Co-mutation STK11/KRAS was found in 156 (1.5%) and 46 (2.8%) patients in the two studies, respectively. Most patients with the STK11/KRAS co-mutation had non-small cell lung cancer (83% and 85% in the two studies, respectively). Among non-small cell lung cancer patients, the STK11 mutation was associated with a worse outcome for patients receiving systemic antitumor therapy, but not immune checkpoint inhibition therapy (HR for OS 1.90 [95% CI 1.36-2.65] and 1.44 [95% CI 0.88-2.37]). Co-mutation STK11/KRAS was also not associated with patient outcome in any of the studies (HR for OS 0.93 [95% CI 0.56-1.52] and 1.09 [95% CI 0.54-2.19]). High tumor mutational burden was associated with better outcome in the cohort of patients receiving immune checkpoint inhibitors. An analogous analysis among patients in the pan-cancer cohort (excluding patients with non-small cell lung cancer) showed STK11 mutations and high tumor mutational burden have a predictive role for the efficacy of immune checkpoint inhibitors, but not STK11/KRAS co-mutation. Conclusions: Co-mutation STK11/KRAS is common among patients with non-small cell lung cancer and is not an independent predictive marker for the efficacy of immune checkpoint inhibitors. Further studies are required to clarify the role of STK11 mutations in immune checkpoint inhibitor treatment response.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
lily发布了新的文献求助10
1秒前
Bryan应助你在烦恼什么采纳,获得10
1秒前
尊敬雪萍发布了新的文献求助10
1秒前
QQ发布了新的文献求助10
1秒前
乖猫要努力应助李傲采纳,获得10
2秒前
勤奋完成签到,获得积分0
2秒前
2秒前
宇宇宇c完成签到,获得积分10
3秒前
CodeCraft应助王铂然采纳,获得10
3秒前
舒心的幻天完成签到,获得积分10
3秒前
小鱼奈子完成签到,获得积分10
4秒前
fireking_sid发布了新的文献求助20
5秒前
2123121321321发布了新的文献求助10
5秒前
充电宝应助尊敬雪萍采纳,获得10
5秒前
5秒前
Lee完成签到 ,获得积分10
6秒前
遊星完成签到,获得积分10
7秒前
风清扬应助欢喜藏今采纳,获得10
7秒前
8秒前
啦啦啦完成签到,获得积分10
8秒前
搞学术的成功女人完成签到,获得积分10
9秒前
9秒前
碧蓝的尔蓝完成签到 ,获得积分10
9秒前
南城完成签到 ,获得积分10
10秒前
不爱吃饭完成签到,获得积分10
10秒前
lyric应助生动醉山采纳,获得10
10秒前
你的风筝完成签到,获得积分10
10秒前
活泼甜瓜完成签到,获得积分10
10秒前
尽平梅愿完成签到,获得积分10
11秒前
啊鲤完成签到,获得积分10
11秒前
奋斗蜗牛完成签到,获得积分10
11秒前
简单点完成签到 ,获得积分10
12秒前
ELITOmiko完成签到,获得积分10
12秒前
简单发布了新的文献求助10
12秒前
HHHH完成签到,获得积分10
12秒前
13秒前
杨道之完成签到,获得积分10
13秒前
NexusExplorer应助yw采纳,获得10
13秒前
13秒前
高分求助中
Nickel, Cobalt and Palladium Catalysed Infarction with Ventricular following rich structural diversity 1000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968608
求助须知:如何正确求助?哪些是违规求助? 3513486
关于积分的说明 11168243
捐赠科研通 3248926
什么是DOI,文献DOI怎么找? 1794540
邀请新用户注册赠送积分活动 875188
科研通“疑难数据库(出版商)”最低求助积分说明 804676